Heparin Contamination May Have Been Deliberate, FDA Says

Author Topic: Heparin Contamination May Have Been Deliberate, FDA Says  (Read 3227 times)

0 Members and 1 Guest are viewing this topic.

DylanBryson

  • Guest
Heparin Contamination May Have Been Deliberate, FDA Says
« on: April 30, 2008, 05:40:38 pm »
Heparin Contamination May Have Been Deliberate, F.D.A. Says


LeRoy Hubley, whose wife and son died from an allergic reaction to contaminated heparin, wipes his eyes while testifying at a House Oversight and Investigations subcommittee hearing on April 29, 2008.

Gardiner Harris
The New York Times
Wednesday, April 30, 2008


WASHINGTON — Federal drug regulators believe that a contaminant detected in a crucial blood thinner that has caused 81 deaths was added deliberately, something the Food and Drug Administration has only hinted at previously.

“F.D.A.’s working hypothesis is that this was intentional contamination, but this is not yet proven,” Dr. Janet Woodcock, director of the Food and Drug Administration’s drug center, told the House Subcommittee on Oversight and Investigations in written testimony given Tuesday.

A third of the material in some batches of the thinner heparin were contaminants, “and it does strain one’s credulity to suggest that might have been done accidentally,” Dr. Woodcock said.

Two weeks ago, Food and Drug Commissioner Andrew C. von Eschenbach told a Senate subcommittee that the contamination was done “by virtue of economic fraud,” but he quickly withdrew the remark, saying he had “probably gone too far.”

Dr. Woodcock’s statement on Tuesday was part of growing chorus that has labeled the heparin contamination as perhaps the most brazen poisoning episode since 1982, when seven people in the Chicago area died after taking Tylenol that had been laced with cyanide.

The Tylenol case led to substantial changes in product packaging, and the heparin contamination has led both Democratic and Republican committee members to call for major changes in the way the F.D.A. functions and is financed.

Tuesday’s hearing was also the first in which family members of those who died were asked to testify.

LeRoy Hubley of Toledo, Ohio, described how both his 65-year-old wife and his 47-year-old son died within a few weeks of each other. Both suffered from a genetic kidney disease that required constant dialysis, for which heparin is routinely used.

“As Christmas music softly played in the background, we each said our goodbyes,” Mr. Hubley said, breaking down in tears. “Then my wife and love of 48 years drifted away.”

He did not know for weeks after their deaths that his wife, Bonnie, and son, Randy, had been given contaminated heparin.

“Now I am left to deal not only with the pain of losing my wife and son, but anger that an unsafe drug was permitted to be sold in this country,” he said.

David G. Strunce, chief executive of Scientific Protein Laboratories, the company that supplied contaminated heparin material to Baxter International, which manufactured and distributed the finished drug, described the contamination as “an insidious act” that “seems to us an intentional act upstream in the supply chain.”

The F.D.A. has identified Changzhou SPL, a Chinese subsidiary of Scientific Protein Laboratories, as the source of the contaminated heparin. A Congressional investigator said the contaminant, oversulfated chondroitin sulfate, cost $9 a pound compared with $900 a pound for heparin.

Mr. Strunce said that his company tried to find the original source of the contamination but was stopped by the Chinese authorities.

Robert L. Parkinson, Baxter’s chairman and chief executive, told the committee, “We’re alarmed that one of our products was used in what appears to have been a deliberate scheme to adulterate a life-saving medication.”

Chinese officials have disputed the F.D.A. contention that the contaminant caused death and injury, and they have insisted on the right to inspect American drug plants if the F.D.A. insists on inspecting Chinese ones.

David Nelson, a Congressional investigator, told the House panel that had the F.D.A. inspected the Chinese plant, the contamination could have been averted.

F.D.A. officials have admitted that they mistakenly failed to conduct an inspection of the Changzhou SPL plant but said that an inspection would not have been able to uncover the contamination.

The agency finally conducted an inspection of the facility in February and found so many problems that the F.D.A. blocked the plant from exporting to the United States. Mr. Nelson was even more critical of Baxter International, which bought heparin ingredients from Changzhou SPL from 2004 through 2008 but did not inspect the facility until September 2007.

The company sent one person who spent one day in the plant, Mr. Nelson said. Five months later, the F.D.A. discovered myriad problems, he said.

“It really is impossible for a plant to have fallen that far out of compliance in five months,” Mr. Nelson said.

Under withering questioning, Dr. Woodcock said that the F.D.A. would need another $225 million annually to inspect every foreign drug plant every other year, the frequency most say is needed. The agency will spend $11 million this year on foreign drug inspections.

There is a growing bipartisan consensus on Capitol Hill that the F.D.A. needs a rapid increase in its budget to ensure the safety of the nation’s drugs, medical devices and food.

The Bush Administration has proposed increasing the agency’s budget next year by only 3 percent to $1.8 billion, not enough to cover even its expected cost increases.


Online TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 10,236
Re: Heparin Contamination May Have Been Deliberate, FDA Says - Followup
« Reply #1 on: December 15, 2008, 10:38:40 pm »
It's interesting that there has been little or no followup in the news. This, in light of the recent exposure of melamine "contamination" .... (see: http://forum.prisonplanet.com/index.php?topic=74031.0 Cyromazine)

http://news.bbc.co.uk/2/hi/asia-pacific/7375057.stm
Page last updated at 11:32 GMT, Wednesday, 30 April 2008 12:32 UK

Heparin contaminated 'on purpose'
America's drugs watchdog believes that Chinese-made ingredients for a blood-thinning drug may have been deliberately contaminated.

The US Food and Drug Administration (FDA) said earlier that a chemical contaminant had been found in some batches of the drug heparin.

It has linked the contaminant to hundreds of severe allergic reactions and dozens of deaths across the US.

An FDA director said when and how the toxin had been introduced was unclear.

...

'Deliberate scheme'

The contaminated stocks were made by Baxter International, using China-based suppliers.

According to the FDA, a chemical called oversulphated chondroitin sulphate has been found in supplies in 13 countries.

Baxter International Chief Executive Robert Parkinson said the company was "alarmed that one of our products was used in what appears to have been a deliberate scheme to adulterate a life-saving medication".

The company has recalled the heparin and imports from the Chinese supplier have been blocked.

Chinese officials have acknowledged the presence of the contaminant.

But they say it is not to blame for the allergic reactions or deaths, citing a lack of incidents in more than 10 other countries which have received the same contaminated stocks.

http://blog.worldvillage.com/business/heparin_contamination_deliberate_fda.html

Heparin Contamination Deliberate: FDA
For the first time since it was revealed that a contaminant in tainted heparin sourced from China may be linked to as many as 81 deaths, officials with the US Food and Drug Administration (FDA) have publicly put forth their belief that the addition of oversulfated chondroitin sulfate was a deliberate act.

....

Chinese officials are not only denying the charge, but a spokesperson with Scientific Protein Laboratories, the Wisconsin-based enterprise that has majority ownership in the vilified Changzhou SPL plant, suggested that when the company attempted to identify the original source of the tainted heparin, they were stopped dead in their tracks by the Chinese.

The heparin contamination issue is thought to be the most serious act of poisoning in decades. A spike in adverse reactions, and a suspected link to an increasing number of deaths led various companies, including Baxter International, to recall very nearly their entire inventory of heparin. The Changzhou SPL plant, as it turns out, supplied the majority of the raw heparin to Baxter and at least two other companies. The facility has since been isolated as the entry point of the contamination, although the source has yet to be identified.

...
Some argue that source may never be found, given the state of the Chinese heparin industry, which is best described as a cottage industry spread out over several provinces. Raw heparin is supplied to Changzhou SPL, through consolidators, from various suppliers, most of which are mom-and-pop shops fashioning the crude heparin from swine intestines. Most of these facilities are unregulated, and conditions are said to be deplorable.



http://www.outsourcing-pharma.com/Contract-Manufacturing/FDA-suspects-heparin-contamination-due-to-fraud


FDA suspects heparin contamination due to fraud
By Gareth Macdonald, 17-Apr-2008

The US Food and Drug Administration (FDA) believes that the contamination of Baxter's blood thinner heparin, which has been linked to 62 deaths in the US, may have been due to the deliberate replacement of some ingredients with cheaper alternatives.

Analysis by the agency recently established that the drug lots in question contained oversulfated chondroitin sulphate, which is a less-expensive, animal cartilage-derived alternative to raw heparin that is not approved for use in medicine. Oversulfated chondroitin sulphate has been implicated in causing the hypersensitivity reactions associated with contaminated heparin.

FDA Commissioner Andrew von Eschenbach told the US Senate on Tuesday that the agency suspected the ingredient switch had been made "by virtue of economic fraud," but added that it would leave further investigation of the matter to Chinese State Food and Drug Administration officials.

http://chinaconfidential.blogspot.com/2008/04/ceo-heparin-contamination-deliberate.html
Tuesday, April 29, 2008 
CEO Says Heparin Contamination Was Deliberate

The chief executive officer of the US pharmaceutical company, Baxter International, says its blood thinner, Heparin, which has been linked to dozens of deaths, appears to have been deliberately contaminated.

Robert Parkinson said Tuesday that a contaminant known as "oversulfated chondroitin sulfate" was found in certain lots of Baxter's Heparin product.

In prepared remarks before a US Congressional subcommittee, Parkinson also said it was difficult to detect the introduction of the contaminant because of how closely it mimicked heparin.

Eighty one deaths have been associated with allergic reactions to tainted doses of heparin.


Then as of May 19 2008 - China declares Heperin "Safe" - end of story....

http://www.outsourcing-pharma.com/Contract-Manufacturing/Heparin-declared-safe-China-remains-nonchalant

Heparin declared "safe", China remains nonchalant
By Kirsty Barnes, 19-May-2008
The US Food and Drug Administration has declared the country's previously-tainted heparin supply to be "safe" due to stronger testing and controls that are now in place. Meanwhile, China continues to distance itself from the matter.

While in Shanghai last week, FDA Health and Human Services (HHS) secretary Mike Leavitt told the media that these tighter controls "will ensure" that no more contaminated heparin products make their way into the US.

"The FDA is satisfied that that which is coming into the United States is safe," he reportedly told the Associated Press (AP).

"We have put in place processes that we believe can ensure the safety of the heparin supply within the United States."

France, Italy, and Denmark, the US, Germany, Switzerland and Japan are among the countries to recall heparin products after a heparin contamination scare over product materials linked to China.

Baxter's heparin was the first to be found to contain the contaminant in February after the FDA received hundreds of reports of serious injuries and/or deaths in patients who had been administered heparin made by the company. Baxter subsequently pulled its product from the market while an investigation ensued.


It has since been revealed by an FDA investigation that the drug lots in question were contaminated with a substance called oversulfated chondroitin sulphate, which is made from animal cartilage and is a cheaper alternative to raw heparin, which is normally derived from pig's intestines. It is not approved for use in medicine.


....

However, he did concede that the current system is only a short-term solution.

"We believe the system that we have for ensuring safety is a good one but completely inadequate for the future," Leavitt told the AP.

"What you'll see from the US is a substantial change in our strategy," he said, eluding to the agency's plans to station officials in overseas posts such as China in order to keep a closer eye on the regulatory situation.

....

In February, FDA inspectors conducted an inspection of the Changzhou SPL plant in question and subsequently issued it with a warning lettter aftger its inspection uncovered "significant deviations" from current good manufacturing practice (GMP) within the facility. It also banned any imports from the company until further notice.

Despite this, it has been reported that in recent government testimony by an FDA inspector that the agency has been barred from investigating the matter further down the supply chain, having been denied complete access to two of Changzhou SPL's suppliers of crude heparin.

...

It is still "too early" to blame OSCS for the deaths of more than 80 people, he said.

He claimed that because Baxter destroyed the recalled drugs it was actually "impossible to determine" exactly what caused the deaths.

Blame is also being laid on the US company Scientific Protein Laboratories that actually owns Changzhou SPL, with China reasoning that the US parent company should "bear responsibility for the plant and its products".
















Offline CFF

  • Member
  • ****
  • Posts: 303
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #2 on: December 16, 2008, 12:14:51 am »
Baxter was the same company who sold the contaminated blood for hemophiliacs, where they all died.
They knew it was contaminated in the past, no difference with this I think.

Offline larsonstdoc

  • Member
  • *****
  • Posts: 21,733
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #3 on: December 16, 2008, 12:18:04 am »



 The key to this story is that these batches were produced in CHINA.

Online TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 10,236
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #4 on: December 16, 2008, 12:32:13 am »
Baxter was the same company who sold the contaminated blood for hemophiliacs, where they all died.
They knew it was contaminated in the past, no difference with this I think.

Yes, and it seems the likely scenerio is for settlements .....

an interesting read:

http://query.nytimes.com/gst/fullpage.html?sec=health&res=9C07E0DE1739F932A25755C0A960958260

Blood, Money and AIDS: Hemophiliacs Are Split;Liability Cases Bogged Down in Disputes

By BARRY MEIER
Published: June 11, 1996
...
Mr. Dubin, like an estimated 6,000 to 10,000 hemophiliacs nationwide, became infected with H.I.V. after receiving a tainted clotting substance made by Baxter and three other companies in the late 1970's and early 1980's. Hundreds of victims had sued. But statutes of limitations prevented thousands more from bringing claims. Mr. Dubin however had not come to lunch to pick a fight. Rather, dissatisfied with the way key plaintiffs' lawyers were handling the litigation, he was on a stealth mission to negotiate, for all those infected, a settlement with the four companies without the knowledge of key plaintiffs' lawyers.

The defendants -- Baxter; Bayer A.G. of Germany; Rhone-Poulenc Rorer Inc., a unit of Rhone-Poulenc S.A. of France, and the Alpha Therapeutic Corporation, a unit of the Green Cross Corporation of Japan -- were also roiled by confusion. Today they are operating in unison. But in the past they often ignored solidarity to protect their own interests, individually discussing settlements, withdrawing them or joining together in various combinations.

In the end, the Committee of Ten Thousand failed to negotiate a deal alone. But its leaders insist their initiative was not in vain. At the very least, they say, they galvanized victims to press for higher compensation. And, according to Baxter documents, they came close to a settlement that could have required Baxter to pay out more than it will under industry's offer last month of $100,000 for each claimant, up to a maximum of $640 million. Hemophiliacs are expected to be polled soon on their interest in the deal.

Online TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 10,236
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #5 on: March 05, 2009, 03:55:11 pm »

Dennis Quaid Accepts Settlement From Hospital in Baxter Heparin

December 18, 2008
Topic: Pharmaceutical Liability

Actor Dennis Quaid has accepted a settlement of $750,000 with Los Angeles' Cedars Sinai Medical Center relating to an accidental overdose of Heparin administered to his newborn twins. Quaid never sued the hospital after the massive overdose that left their newborn twins sick for some time, but they did file a lawsuit with the manufacturer of the Heparin, Baxter Healthcare Corporation.

The high-profile case has hogged headlines and the limelight because of the celebrity nature of the plaintiffs. In November 2007, the twins, Zoe Grace and Thomas Boone were being treated at the hospital for a staph infection. A nurse administered a dose of heparin that was a staggering 1000 times the normal amount. The standard recommended dosage for the twins was 10 units apiece. The nurse administered a dosage of 10,000 units apiece. The twins have since then recovered from their terrible trauma, and are now a year old.

Quaid filed a lawsuit against Baxter for the poor labeling and packaging of its heparin bottles. The lawsuit seeks more than $50,000 in damages from the company and alleged that the bottles of the10 unit dosage bottles of Heparin were too similar to the bottles that contained heparin of 10,000 units. The misleading labeling caused the nurse who was administering the dosage to get confused, the lawsuit contended. The newborn twins received an adult dosage of the blood thinner that could have been prevented by proper labeling of product, accord to the lawsuit.

Baxter countered the allegations claiming that it had started using different packaging earlier that year. The labels are now a different color as compared to the ones that were in use when the twins fell sick. Still that doesn't take away from the fact that the company neglected to provide proper labeling for the bottles and never recalled the bottles with the old labeling. The print on the label on the bottle that was used to administer the dosage to the twins was tiny and the only thing differentiating the lower and higher dose bottles at a glance was the different colored cap.

Quaid has taken his crusade against Baxter in general and malpractice of the pharmaceutical industry at large to the highest echelons of power. Last year he testified at a Congressional hearing, arguing against exempting big pharmaceutical companies from their share of liability in medical errors like the one that happened with his children. He admitted that he had never been a big one for lawsuits, but his experience had opened his eyes to the fact that when big companies are negligent, then the courts may provide the only path to justice.

Nobody could say that Quaid filed the liability claim against Baxter for the money. It was not just that his children were seriously injured or ill after the massive overdose. It was the fact that a company could simply turn around and say it had no liability at all in the matter, never mind that the two bottles were difficult to tell apart.


Dennis Quaid Accepts Settlement From Hospital in Baxter Heparin Case

Dec 16, 2008

LOS ANGELES, Dec. 16 (UPI) -- Actor Dennis Quaid has agreed to a $750,000 settlement in his case against the Los Angeles hospital that accidentally overdosed his newborn twins with Heparin.

People.com said the agreement that would settle Quaid's and his wife Kimberly's lawsuit against Cedars-Sinai Medical Center, regarding the 2007 blood-thinner mishap, is pending the approval of a Los Angeles judge.

"The settlement is the result of extensive negotiations between the parties and their respective legal representatives, and is intended to avoid the time, expense and uncertainty of litigation," said papers filed in Los Angeles Superior Court Monday.

Quaid's lawyer declined to comment on the matter when contacted by People magazine.

Although the mistake nearly cost Thomas Boone and Zoe Grace Quaid their lives, the actor's children have since recovered from the overdose and are now healthy, the magazine said on its Web site.

The hospital has apologized and promised to train its staff better to avoid mistakes like this in the future. The California Department of Public Health has also fined the facility $25,000, People.com noted.

Online TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 10,236
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #6 on: March 05, 2009, 04:27:22 pm »
http://findarticles.com/p/articles/mi_qn4183/is_20090123/ai_n31294352
Heparin actions trigger lawsuit in U.S. District Court in Greenbelt

On Jan. 7, 2008, Randy Hubley Sr. started a course of dialysis at a Toledo, Ohio center and was given the drug heparin, a commonly used blood thinner -- the same medicine his mother had received a month earlier during her dialysis treatment.

And, like his mother, Bonnie Hubley, Randy died shortly after being given the drug. The Hubley family's subsequent lawsuits are just two of more than 70 federal actions that have been filed since April 2008, when the Food and Drug Administration linked a contaminant in the raw material to severe allergic reactions that caused the deaths of at least 40 people.

Seeing the lawsuits mounting, The Charter Oak Fire Insurance Co. and Travelers Property Casualty Co. of America are suing to nullify the policies held by Scientific Protein Laboratories' parent company, the Bethesda-based buyout firm American Capital Ltd.

While the maker of heparin, Baxter International Inc., is the primary target of the now class action lawsuit, so is Wisconsin- based Scientific Protein Laboratories, whose joint venture in China has been blamed for producing the contaminated material.

Charter Oak and Travelers filed their lawsuit last week in the U.S. District Court in Greenbelt, contesting coverage sought by American Capital and Scientific Protein Laboratories under the existing policies for the pending heparin litigation.

The insurance companies argue that in its applications for coverage, American Capital never said it had any subsidiaries, and never mentioned Scientific Protein Laboratories or that company's joint venture in China that produced the raw heparin in question.

"Now, in direct contradiction to that intent and representation, American Capital seeks insurance coverage from Charter Oak and Travelers for underlying lawsuits that relate to purported subsidiaries of American Capital," the lawsuit states.

"In the insurance applications provided by American Capital to Charter Oak and Travelers, American Capital was asked whether it had any subsidiaries. American Capital answered 'no,'" the lawsuit states. "American Capital provided false answers to Charter Oak and Travelers regarding the non-existence of subsidiaries."

Majority owner

In an Aug. 18, 2006, news release, American Capital announced it had purchased approximately 87 percent of Scientific Protein Laboratories LLC. In its last quarterly earnings report filed with the Securities and Exchange Commission, American Capital said the Scientific Protein Laboratories deal cost $174.5 million and the company had a fair market value of $186.5 million.

The insurance companies argue that in addition to not disclosing that the buyout firm had subsidiaries, American Capital failed to disclose it had any foreign subsidiaries or joint ventures or that it distributed any foreign products.

Additionally, Charter Oak and Travelers claim that on Dec. 2, 2008, American Capital and SPL reached an agreement with Baxter International over the heparin lawsuits that includes making payments to Baxter and assigning "rights to insurance proceeds and benefits."

"American Capital and SPL made these agreements in disregard of the express written warnings from Charter Oak and Travelers not to make any voluntary payments or settlements in the heparin lawsuits," the complaint reads.

On Wednesday, American Capital spokeswoman Jennifer Burke declined to comment on the alleged settlement and said the company would not comment on pending litigation. The company has not filed anything with the SEC about the settlement.

Baxter, in an October SEC filing, said recalling the tainted heparin in the first quarter of 2008 cost the company $19 million. It said 2007 sales of heparin were $30 million.

http://www.schmidtandclark.com/Baxter-Heparin-Recall/

Nationwide Baxter Heparin Recall Alert

Do I have a Baxter Heparin Recall Lawsuit?
The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Baxter Heparin Recall lawsuits. We are handling individual litigation nationwide and currently accepting new Heparin cases in all 50 states.

Offline scoffer

  • Member
  • *****
  • Posts: 1,019
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #7 on: March 05, 2009, 04:42:17 pm »
Heparin was produced in China, it's production was off-shored by Baxter to save money, avoid paying taxes. What's more it is highly likely that the Dept. of Health and Human Services knew of this problem prior to the discovery of the contamination, I reported it as an adverse reaction numerous times before contamination was known, the response I got was that heparinization is a proceedure, therefore it cannot be an adverse drug reaction. I argued and spent hours researching, but to no avail. These bastards have blood on their hands either due to negligence or corporate favoritism. Dept. of Health and Human Services indeed!

I'm not really supposed to talk about this, but this subject really ticks me off and I don't care if they come after me anymore.

Offline dissident99

  • Member
  • ****
  • Posts: 440
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #8 on: March 05, 2009, 05:00:12 pm »
Does anybody know who owns Baxter ??

http://en.wikipedia.org/wiki/Baxter_International

Not verified but supposedly John Kelley owns 4000 shares .. but again it has not been verified and who knows what
4000 shares mean .. 

http://caps.fool.com/Pitch/BAX/1978969/john-keeley-owns-4000-shares-o.aspx
"The only thing necessary for the triumph of evil is for good men to do nothing" -Edmund Bourke

"They that can give up essential liberty to obtain
a little temporary safety deserve neither liberty nor safety"
- Benjamin Franklin

Online TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 10,236
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #9 on: March 05, 2009, 05:34:05 pm »
The front men:

http://www.baxter.com/about_baxter/company_profile/company_leadership/index.html

Board of Directors of Baxter International Inc.
   
Walter E. Boomer  Former Chairman and CEO, Rogers Corporation
 
Blake E. Devitt  Former Senior Audit Partner, Ernst & Young LLP
 
John D. Forsyth  Chairman and CEO, Wellmark Blue Cross and Blue Shield
 
Gail D. Fosler  President and Chief Economist, The Conference Board
 
James R. Gavin III, M.D., Ph.D.  CEO and Chief Medical Officer, Healing Our Village, Inc.
 
Peter S. Hellman  Former President, Chief Financial and Administrative Officer, Nordson Corporation
 
Wayne T. Hockmeyer, Ph.D.  Founder and Former Chairman and CEO, MedImmune, Inc.
 
Joseph B. Martin, M.D., Ph.D.
 Professor of Neurobiology and Former Dean of the Faculty of Medicine, Harvard Medical School
 
Robert L. Parkinson, Jr.  Chairman and CEO, Baxter International Inc.
 
Carole Shapazian  Former Executive VP, Maytag Corporation
 
Thomas T. Stallkamp  Industrial Partner, Ripplewood Holdings LLC
 
K. J. Storm  Former Chairman of the Executive Board, AEGON N.V. (The Netherlands)
 
Albert P.L. Stroucken  Chairman, President and Chief Executive Officer, Owens-Illinois, Inc.
 
 
Executive Officers

Joy A. Amundson  Corporate Vice President - President, BioScience
 
Peter J. Arduini  Corporate Vice President - President, Medication Delivery
 
Robert M. Davis  Corporate Vice President and Chief Financial Officer
 
J. Michael Gatling  Corporate Vice President - Manufacturing
 
John J. Greisch  Corporate Vice President - President, International
 
Susan R. Lichtenstein  Corporate Vice President and General Counsel
 
Jeanne K. Mason  Corporate Vice President - Human Resources
 
Bruce McGillivray  Corporate Vice President - President, Renal
 
Robert L. Parkinson, Jr.  Chairman of the Board, Chief Executive Officer and President
 
Norbert G. Riedel  Corporate Vice President and Chief Scientific Officer
 
Karenann Terrell  Corporate Vice President and Chief Information Officer
 
Cheryl L. White  Corporate Vice President - Quality
   
 
Corporate Officers 
 
Carlos Alonso  Corporate Vice President -- President, Latin America
 
Michael J. Baughman  Corporate Vice President and Controller
 
Robert J. Hombach   Corporate Vice President and Treasurer
 
Gerald Lema  Corporate Vice President - President, Asia Pacific
 
Peter Nicklin Corporate Vice President - President, Europe
 
David P. Scharf  Corporate Vice President and Corporate Secretary

Online TahoeBlue

  • Global Moderator
  • Member
  • *****
  • Posts: 10,236
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #10 on: March 05, 2009, 06:11:02 pm »

http://finance.yahoo.com/q/mh?s=BAX

Baxter International Inc. (BAX)

% of Shares Held by All Insider and 5% Owners:  0%
% of Shares Held by Institutional & Mutual Fund Owners:  85%
% of Float Held by Institutional & Mutual Fund Owners:  85%
Number of Institutions Holding Shares:  847

MAJOR DIRECT HOLDERS (FORMS 3 & 4)
 
Holder Shares Reported
PARKINSON ROBERT L JR 187,971 14-Mar-08
MCGILLIVRAY BRUCE      159,040 28-Aug-08
GATLING JAMES M         139,688 9-Jul-08
GREISCH JOHN J             90,419 26-Jan-09
ARDUINI PETER J            86,255 20-Aug-08
 

TOP INSTITUTIONAL HOLDERS  (only ~30 percent of all shares....)

Holder Shares % Out Value* Reported
Barclays Global Investors UK Holdings Ltd 30,174,940 4.87 $1,617,075,034 31-Dec-08
FMR LLC                                             28,371,609 4.57 $1,520,434,526 31-Dec-08
STATE STREET CORPORATION                26,083,487 4.21 $1,397,814,068 31-Dec-08
VANGUARD GROUP, INC. (THE)                20,023,933 3.23 $1,073,082,569 31-Dec-08
AXA                                                  19,647,612 3.17 $1,052,915,527 31-Dec-08
JENNISON ASSOCIATES LLC                  15,819,520 2.55 $847,768,076 31-Dec-08
PRICE (T.ROWE) ASSOCIATES INC          13,666,097 2.20 $732,366,138 31-Dec-08
GOLDMAN SACHS GROUP INC                 13,017,729 2.10 $697,620,097 31-Dec-08
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO 12,975,694 2.09 $695,367,441 31-Dec-08
JANUS CAPITAL MANAGEMENT, LLC         11,718,985 1.89 $628,020,406 31-Dec-08

Offline Monkeypox

  • Member
  • *****
  • Posts: 16,849
  • He Loved Big Brother
    • Monkeypox
Re: Heparin Contamination May Have Been Deliberate, FDA Says
« Reply #11 on: March 05, 2009, 06:33:12 pm »
Yessir, let's keep off-shoring our food and drug production to China.  It's working out SO FVCKING WELL.
War Is Peace - Freedom Is Slavery - Ignorance Is Strength


"Educate and inform the whole mass of the people... They are the only sure reliance for the preservation of our liberty."

—Thomas Jefferson